Liminal Custody, wallet infrastructure and custody technology leader, today released a major strategic report https://www.liminalcustody.com/insights/the-walled-garden/ that serves as a definitive blueprint for banks and financial institutions looking to be a part of the digital asset reality. Large traditional banks are already making technology investments to prepare for this shift from TradFi to DeFi. The research (https://www.liminalcustody.com/insights/the-walled-garden/) confirms an urge...

Toshiba Electronic Devices & Storage Corporation ("Toshiba") has started providing engineering samples of “TB9104FTG,” a gate driver[1] for bridge circuits used in high-current automotive brushed DC motors, suitable for body system applications such as power back doors, power sliding doors, and power seats. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128677664/en/Toshiba: TB9104FTG, a gate driver for bridge circuits used i...

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quart...

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and yea...

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined An...